Pyxis Oncology is in good handsIt’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline.
Next report date
Report period
Q1 2024
EPS estimate
−0.24USD
Revenue estimate
3.30 MUSD
−1.86USD
−73.79 MUSD
46.27 M
About Pyxis Oncology, Inc.
Sector
CEO
Lara S. Sullivan
Headquarters
Boston
Website
Employees (FY)
50
Founded
2018
FIGI
BBG00PQFFCV5
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where PYXS is featured.
Frequently Asked Questions
The current price of PYXS is 4.30 USD — it has decreased by 3.37% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pyxis Oncology, Inc. stocks are traded under the ticker PYXS.
Pyxis Oncology, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
PYXS stock is 6.82% volatile and has beta coefficient of 1.90. Check out the list of the most volatile stocks — is Pyxis Oncology, Inc. there?
PYXS earnings for the last quarter are −0.56 USD per share, whereas the estimation was −0.51 USD resulting in a −10.48% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about Pyxis Oncology, Inc. earnings.
Yes, you can track Pyxis Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
PYXS stock has fallen by 11.52% compared to the previous week, the month change is a 19.44% rise, over the last year Pyxis Oncology, Inc. has showed a 44.30% increase.
PYXS net income for the last quarter is −15.60 M USD, while the quarter before that showed −23.05 M USD of net income which accounts for 32.33% change. Track more Pyxis Oncology, Inc. financial stats to get the full picture.
Today Pyxis Oncology, Inc. has the market capitalization of 249.97 M, it has decreased by 3.41% over the last week.
No, PYXS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PYXS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pyxis Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 50.00 employees. See our rating of the largest employees — is Pyxis Oncology, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pyxis Oncology, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pyxis Oncology, Inc. stock shows the buy signal. See more of Pyxis Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Pyxis Oncology, Inc. future price: according to them, PYXS price has a max estimate of 12.00 USD and a min estimate of 7.00 USD. Read a more detailed Pyxis Oncology, Inc. forecast: see what analysts think of Pyxis Oncology, Inc. and suggest that you do with its stocks.